<!DOCTYPE html><html prefix="og: http://ogp.me/ns#" lang="zh">
<!-- Mirrored from cn.nytimes.com/business/20130723/c23drug/dual/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:18:31 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head><meta charset="UTF-8"><!-- Browser render  --><meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"><meta name="renderer" content="webkit"><!-- End Browser render --><meta name="keywords" content=""><meta name="description" content="英国制药企业葛兰素史克内部审计发现，公司在华研发中心存在不当操作，如不报告动物试验结果，未妥善监督临床试验等。这些问题反映了外国企业在华扩张时忽略规范管理的风险。"><meta id="uuid" name="uuid" content="2930c00109aad294d78c13a62efa57b6"><meta id="headline" name="headline" content="内部审计暴露英国药商在华研发中心不当操作 - 世界经济观察报中文网"><meta id="byline" name="byline" content="KATIE THOMAS"><meta id="date" name="date" content="2013-07-23T02:47:57.000Z"><link rel="alternate" href="../index.html" hreflang="zh-Hans"><link rel="alternate" href="../zh-hant/index.html" hreflang="zh-Hant"><link rel="canonical" href="../index.html"><link rel="alternate" type="application/rss+xml" href="https://cn.nytimes.com/rss/"><meta name="apple-itunes-app" content="app-id=807498298, app-argument=nytimescn://article:2930c00109aad294d78c13a62efa57b6"><meta name="lang" property="lang" content="zh-cmn-hans"><!-- Apple IOS safari private meta --><link rel="apple-touch-icon-precomposed" sizes="144×144" href="../../../../../static01.nyt.com/images/icons/ios-ipad-144x144.png"><link rel="apple-touch-icon-precomposed" sizes="114×114" href="../../../../../static01.nyt.com/images/icons/ios-iphone-114x144.png"><link rel="apple-touch-icon-precomposed" href="../../../../../static01.nyt.com/images/icons/ios-default-homescreen-57x57.png"><meta name="apple-mobile-web-app-title" content="内部审计暴露英国药商在华研发中心不当操作 - 世界经济观察报中文网"><meta name="apple-mobile-web-app-capable" content="yes"><!-- End Apple IOS safari private meta --><!-- Viewport and mobile --><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=no,maximum-scale=1,minimum-scale=1,minimal-ui"><!-- End viewport and mobile --><meta http-equiv="Cache-Control" content="no-siteapp"><meta name="format-detection" content="telephone=no"><meta name="HandheldFriendly" content="true"><meta name="MobileOptimized" content="320"><meta name="x5-orientation" content="portrait"><meta name="full-screen" content="yes"><meta name="x5-fullscreen" content="true"><meta name="browsermode" content="application"><meta name="x5-page-mode" content="app"><meta name="msapplication-tap-highlight" content="no"><meta property="og:title" content="内部审计暴露英国药商在华研发中心不当操作"><meta property="og:type" content="article"><meta property="og:url" content="../index.html"><meta property="og:description" content="英国制药企业葛兰素史克内部审计发现，公司在华研发中心存在不当操作，如不报告动物试验结果，未妥善监督临床试验等。这些问题反映了外国企业在华扩张时忽略规范管理的风险。"><meta property="og:site_name" content="世界经济观察报中文网"><meta property="article:publisher" content="https://www.facebook.com/nytimeschinese"><meta property="article:published_time" content="2013-07-23T02:47:57.000Z"><meta property="fb:pages" content="354478527979178"><meta property="fb:app_id" content="1752616314982485"><meta property="og:image" content="../../../../../static01.nyt.com/images/2013/07/23/business/AUDIT/AUDIT-articleLarge.html"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:url" content="../index.html"><meta property="twitter:title" content="内部审计暴露英国药商在华研发中心不当操作"><meta property="twitter:description" content="英国制药企业葛兰素史克内部审计发现，公司在华研发中心存在不当操作，如不报告动物试验结果，未妥善监督临床试验等。这些问题反映了外国企业在华扩张时忽略规范管理的风险。"><meta property="twitter:domain" content="cn.nytimes.com"><meta property="twitter:site" content="@nytchinese"><meta property="twitter:creator" content="@nytchinese"><meta property="twitter:image:src" content="../../../../../static01.nyt.com/images/2013/07/23/business/AUDIT/AUDIT-articleLarge.html"><meta name="PT" content="article"><meta name="PST" content="News"><meta name="CG" content="business"><meta name="SCG" content=""><meta name="sourceApp" content="nyt-china-web"><meta name="ptime" content="20130723024757"><meta name="utime" content="20130723024757"><meta name="pdate" content="20130723"><meta name="dat" content="Jul. 23, 2013"><meta name="hdl" content="内部审计暴露英国药商在华研发中心不当操作"><meta name="byl" content="KATIE THOMAS"><meta name="lp" content="英国制药企业葛兰素史克内部审计发现，公司在华研发中心存在不当操作，如不报告动物试验结果，未妥善监督临床试验等。这些问题反映了外国企业在华扩张时忽略规范管理的风险。"><link rel="shortcut icon" href="https://static01.nyt.com/favicon.ico"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/style-flex.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/web/style.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/nytcn_core/article.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/slideshow/slideshow.min619b.css?v=f1810d8"><link rel="stylesheet" href="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/css/cookie-banner/style.min619b.css?v=f1810d8"><title>内部审计暴露英国药商在华研发中心不当操作 - 世界经济观察报中文网</title></head><script>var js_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/js";
 var imgs_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style/imgs";
 var style_static_path = "https://d1f1eryiqyjs0r.cloudfront.net/style";
 var site = 1;
 var sectionName = "business";
 var adTyp = "art";
 var cookieString = {
     "title": "您的跟踪器设置",
     "headline": "我们使用 cookie 做什么？",
     "summary": '<p>我们利用cookies和类似的技术识别您的重复访问和偏好。我们还使用它们来衡量广告系列的效果，定位广告并分析和网站流量。更多关于cookies的信息（包括如何停用），<a id="JSCookiePolicyLink" href="https://www.nytimes.com/zh-hans/privacy/cookie-policy" rel="noreferrer noopener" target="_blank" data-testid="GDPR-policy">请查看我们的“Cookie政策”</a>。</p><p>自2020年7月20日起，我们将根据您在我们服务中所访问的内容类型向您显示我们认为与您的兴趣相关的广告。您可以<a href="https://www.nytimes.com/zh-hans/privacy/cookie-policy#how-do-i-manage-trackers" rel="noreferrer noopener" target="_blank" data-testid="GDPR-objection">提出反对</a>。希望了解更多信息，请参见我们的<a href="https://nytimes.com/zh-hans/privacy/privacy-policy#we-allow-for-personalized-advertising-on-times-services" rel="noreferrer noopener" target="_blank" data-testid="GDPR-privacy">隐私政策</a>。</p><p>通过在此处点击“我接受”或者“X”，您将被视为同意使用cookies。您随时可以通过我们的Cookie政策来更改您的跟踪器偏好。</p>',
     "button": "接受",
     "trackerButton": "您的跟踪器设置",
     "rejectButton": "拒绝所有",
     "lang": 'zh-hans',
     "trackerLink": "https://www.nytimes.com/zh-hans/privacy/cookie-policy",
 };
 var purrString = {
     "button": "请勿出售我的个人信息",
     "snackbar": "你的设置已经保存在此浏览器和设备上。如果你清除了 cookie，这些设置也会被清除。",
     "snackbarError": "Something went wrong",
     "optedOutText": "我们不再出售您的个人信息",
     "CFALinkText": "California Notices",
     "purrPopupTitle": "Your request to not sell your data will be stored for this browser and device",
     "purrPopupSummary": "If you clear your cookies, your preference will be forgotten. As a California resident, you have additional rights under the California Consumer Privacy Act of 2018. While The New York Times Company does not “sell” personal information of its readers as the term “sell” is traditionally understood, “sell” under the CCPA is broadly defined. To learn more, review the text below.",
     "purrPopupButton": "DISMISS",
     "purrPopupScrollContent": '<p>The New York Times Company does not sell personal information of its readers as the term “sell” is traditionally understood. But “sell” under the CCPA is broadly defined. It includes the sharing of personal information with third parties in exchange for something of value, even if no money changes hands. For example, sharing an advertising or device identifier to a third party may be considered a “sale” under the CCPA. </p><p>To the extent The New York Times Company “sells” your personal information (as the term “sell” is defined under the CCPA), you have the right to opt-out of that “sale” on a going-forward basis at any time. To exercise this right, click the “Do Not Sell My Personal Information” link in the footer of our website or under your “Account,” which you have already done. You can also submit a request to opt-out by emailing us at privacy@nytimes.com with the subject line “California Resident - Do Not Sell.”</p><p>Once you have opted out, you will see a change to “We No Longer Sell Your Personal Information.” If you have an account with certain Times Services (specifically nytimes.com, cooking.nytimes.com, nytimes.com/crosswords, the New York Times app, the New York Times Cooking app and the New York Times Crossword app) and are logged in, we will save your preference and honor your opt-out request across browsers and devices so long as you remain logged in. If you are not logged in, or do not have an account with any Times Services listed above, your opt-out of the “sale” of personal information will be specific to the browser or device from which you have clicked “Do Not Sell My Personal Information” and until you clear your cookies (or local storage in apps) on this browser or device. </p><p>If your browser or device is using a “do not track” setting, we will detect it and honor it on that specific browser or device only. If you wish to have a “do not track” experience across all of your browsers and devices, please make sure that all of your browsers and devices are set on “do not track.”</p><p>After you opt out of the “sale” of your personal information, we will no longer “sell” your personal information to third parties (except in an aggregated or de-identified manner so it is no longer personal information), but we will continue to share your personal information with our service providers, which process it on our behalf. Exercising your right to opt out of the “sale” of your personal information does not mean that you will stop seeing ads on our sites and apps. </p><p>To opt-out of interest-based advertising as much as technically possible, go to <a href="http://www.nytimes.com/privacy/cookie-policy#how-do-i-manage-trackers" target="_blank">“How Do I Manage Trackers”</a> in our Cookie Policy. To opt out of the “sale” of your personal information from participating companies, please visit the Digital Advertising Alliance <a href="https://optout.privacyrights.info/?c=1" target="_blank">website</a> or <a href="https://www.privacyrights.info/appchoices" target="_blank">apps</a>. We do not control these opt-out mechanisms and are not responsible for their operation.</p><p>You can designate someone else to make a request on your behalf. To protect your information, we will ask for a signed permission from you authorizing the other person to submit a request on your behalf. We will contact you to verify your identity before we respond to your authorized agent’s request.<p/><p>After 12 months, we may ask you if you want to opt into the “sale” of your personal information.</p><p>For further information, please refer to our <a href="http://www.nytimes.com/privacy/privacy-policy" target="_blank">Privacy Policy.</a></p>',
     "lang": 'zh-hans'
 };
 cbSectionName = "business";
 cbByline = "KATIE THOMAS";</script><!-- Google Tag Manager --><script>(function(w,d,s,l,i){
     w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});
     var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';
     j.async=true;j.src='../../../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;
     f.parentNode.insertBefore(j,f);
 })(window,document,'script','dataLayer','GTM-KTDZV8V');</script><!-- End Google Tag Manager --><!-- chartbeat --><script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script><!-- /chartbeat --><body class="news"><main class="container-fluid main clearfix"><header class="row title-bar"><div class="nav-button default" id="menuBtn"><i class="icon-bars"></i></div><h1 class="logo"><a href="/"><svg role="img" aria-label="" width="90%" height="90%"><image width="100%" height="100%" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="/d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hans%402x.png" src="../../../../../d1f1eryiqyjs0r.cloudfront.net/style/imgs/mweb/nytimes-zh-hans%402x.png" alt="" border="0"></image></svg></a></h1><div class="nav-button default" id="gearBtn"><i class="icon-gear"></i></div><div class="popup gear-popup"><div class="tips-container"><div class="tips-border"></div><div class="tips-inner"></div></div><div class="popup-container"><div class="popup-body"><div class="setting-title">简繁中文</div><div class="setting-option"><a href="../index024e.html?changeLang=zh-hans" class="active">简体 </a><a href="../index27d8.html?changeLang=zh-hant">繁体</a></div><div class="setting-title">世界经济观察报 出版语言</div><ul class="menu-list"><li><a href="https://www.nytimes.com/">ENGLISH (英语)</a></li><li><a href="https://www.nytimes.com/es/">ESPAÑOL (西班牙语)</a></li></ul><div class="setting-title">字体大小</div><div class="setting-option"><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="small"> 小</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="normal" checked="checked"> 中</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="large"> 大</label></div><div class="form-check form-check-inline"><label class="form-check-label"><input class="form-check-input font-size" type="radio" name="changeFontSizeRadio" value="xlarge"> 超大</label></div></div></div></div></div></header><div class="top_banner_ad" id="topad" data-target="{&quot;pos&quot;:&quot;top&quot;,&quot;adv&quot;:&quot;&quot;}"></div><div class="article-area"><div class="setting-bar row"><div class="col-4 section-title"><h3>商业与经济</h3></div><div class="col-8 setting-btns"><div class="row"><div class="col-6"><ul class="dual-btn"><li><a href="../index.html"><span class="setting-btn-text">中文</span> <span class="setting-btn-text-mobile">中</span></a></li><li><a href="javascript:;" class="active"><span class="setting-btn-text">中英双语</span> <span class="setting-btn-text-mobile">双语</span></a></li><li><a href="#" target="_blank"><span class="setting-btn-text">英文 <i class="icon-share-square"></i> </span><span class="setting-btn-text-mobile">英</span></a></li></ul></div><div class="col-6 share-tools-top-container"><ul class="share-tools mobile-article"><li><a href="http://v.t.sina.com.cn/share/share.php?&amp;title=%E5%86%85%E9%83%A8%E5%AE%A1%E8%AE%A1%E6%9A%B4%E9%9C%B2%E8%8B%B1%E5%9B%BD%E8%8D%AF%E5%95%86%E5%9C%A8%E5%8D%8E%E7%A0%94%E5%8F%91%E4%B8%AD%E5%BF%83%E4%B8%8D%E5%BD%93%E6%93%8D%E4%BD%9C&amp;url=https://cn.nytimes.com/business/20130723/c23drug/" target="_blank"><i class="icon-weibo"></i></a></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20130723/c23drug/" data-headline="%E5%86%85%E9%83%A8%E5%AE%A1%E8%AE%A1%E6%9A%B4%E9%9C%B2%E8%8B%B1%E5%9B%BD%E8%8D%AF%E5%95%86%E5%9C%A8%E5%8D%8E%E7%A0%94%E5%8F%91%E4%B8%AD%E5%BF%83%E4%B8%8D%E5%BD%93%E6%93%8D%E4%BD%9C"> --><!-- <i class="icon-wechat"></i> --><!-- </a> --><!-- </li> --><li><a href="https://www.facebook.com/sharer/sharer.php?u=https://cn.nytimes.com/business/20130723/c23drug/" trage="_blank"><i class="icon-facebook"></i></a></li><li><a href="https://plus.google.com/share?url=https://cn.nytimes.com/business/20130723/c23drug/" target="_blank"><i class="icon-google"></i></a></li><li><a href="https://twitter.com/share?text=%E5%86%85%E9%83%A8%E5%AE%A1%E8%AE%A1%E6%9A%B4%E9%9C%B2%E8%8B%B1%E5%9B%BD%E8%8D%AF%E5%95%86%E5%9C%A8%E5%8D%8E%E7%A0%94%E5%8F%91%E4%B8%AD%E5%BF%83%E4%B8%8D%E5%BD%93%E6%93%8D%E4%BD%9C&amp;url=https://cn.nytimes.com/business/20130723/c23drug/" target="_blank"><i class="icon-twitter"></i></a></li><li><div class="line-it-button" data-lang="zh_Hant" data-type="share-g" data-url="https://cn.nytimes.com/business/20130723/c23drug/" style="display: none;"></div><script src="/d.line-scdn.net/r/web/social-plugin/js/thirdparty/loader.min.js" async="async" defer="defer"></script></li><!-- <li> --><!-- <a href="javascript:void(0);" class="JS_shareForQrcode" data-url="https://cn.nytimes.com/business/20130723/c23drug/" data-headline="%E5%86%85%E9%83%A8%E5%AE%A1%E8%AE%A1%E6%9A%B4%E9%9C%B2%E8%8B%B1%E5%9B%BD%E8%8D%AF%E5%95%86%E5%9C%A8%E5%8D%8E%E7%A0%94%E5%8F%91%E4%B8%AD%E5%BF%83%E4%B8%8D%E5%BD%93%E6%93%8D%E4%BD%9C"> --><!-- <i class="icon-qrcode"></i> --><!-- </a> --><!-- </li> --></ul><div class="share-btn"><i class="icon-forward"></i></div></div></div></div></div><article class="article-content article-dual font-normal"><div class="article-header"><header><small></small><h1>内部审计暴露英国药商在华研发中心不当操作</h1><h1 class="en-title">Drug Research in China Falls Under a Cloud</h1></header><div class="byline-row"><div class="byline-box"><div class="byline"><address>KATIE THOMAS</address><time pudate="2013-07-23 02:47:57" datetime="2013-07-23 02:47:57">2013年7月23日</time></div><div class="share-btn"><i class="icon-forward"></i></div></div></div></div><figure class="article-span-photo"><img src="../../../../../static01.nyt.com/images/2013/07/23/business/AUDIT/AUDIT-master1050.html" width="1050" height="700" alt="葛兰素史克的上海研发中心开发神经药物。一次审计发现该公司在这里进行研究的方式存在问题。"><figcaption><span>葛兰素史克的上海研发中心开发神经药物。一次审计发现该公司在这里进行研究的方式存在问题。</span> <cite>China Stringer Network/Reuters</cite></figcaption></figure><div class="row"><section class="article-body"><div class="article-partial"><div class="article-body-item col-lg-5"><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Executives at the British drug maker GlaxoSmithKline were warned nearly two years ago about critical problems with the way the company conducted research at its drug development center in China, exposing it to potential financial risk and regulatory action, an internal audit found.</div></div><div class="col-lg-6"><div class="article-paragraph">英国制药商葛兰素史克公司（GlaxoSmithKline，简称GSK）高管在近两年前就曾收到警告，警告针对的是与该公司中国药物开发中心研究方式有关的关键问题，将其暴露在潜在的财务风险和监管行动之下。前述问题是在一次内部审计中发现的。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The confidential document from November 2011, obtained by The New York Times, suggests that Glaxo’s problems may go beyond the sales practices that are currently at the center of a bribery and corruption scandal in China. They may extend to its Shanghai research and development center, which develops neurology drugs for Glaxo.</div></div><div class="col-lg-6"><div class="article-paragraph">《世界经济观察报》获得的这份2011年11月的机密文件显示，GSK的问题可能不限于销售手法，该销售手法目前正处在中国的一起贿赂和腐败丑闻的中心。GSK的问题可能还涉及其上海研发中心，该中心为GSK开发神经药物。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The failings, some experts said, underscore the problems that can arise when major drug companies export their scientific development to emerging markets like China.</div></div><div class="col-lg-6"><div class="article-paragraph">一些专家称，这些失误凸显了大型制药商将科研成果出口到中国等新兴市场时可能面临的问题。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Since 2006, 13 of the top 20 global drug makers have set up research and development centers in China, <a rel="noopener noreferrer" target="_blank" href="http://www.mckinseychina.com/2012/09/03/healthcare-in-china-entering-uncharted-waters-2/">according to a report</a> by McKinsey & Company. “It’s cheaper to do research there,” said Eric G. Campbell, a professor of health care policy at Harvard Medical School. However, “I have absolutely no doubt that with cheaper research comes greater risk.”</div></div><div class="col-lg-6"><div class="article-paragraph">根据麦肯锡公司(McKinsey & Company)的<a rel="noopener noreferrer" target="_blank" href="http://www.mckinseychina.com/2012/09/03/healthcare-in-china-entering-uncharted-waters-2/" title="Link: http://www.mckinseychina.com/2012/09/03/healthcare-in-china-entering-uncharted-waters-2/">一份报告</a>，从2006年起，全球前20名的制药商当中有13家在中国建立了研发中心。“在那里做研究会便宜一些，”哈佛大学医学院(Harvard Medical School)的医疗保健政策教授埃里克·G·坎贝尔(Eric G. Campbell)说。“（然而）我敢肯定，较便宜的研究会带来较大的风险。”</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Auditors found that researchers did not report the results of animal studies in a drug that was already being tested in humans, a breach that one medical ethicist described as a “mortal sin” in the world of drug research. They also concluded that workers at the research center did not properly monitor clinical trials and paid hospitals in ways that could be seen as bribery.</div></div><div class="col-lg-6"><div class="article-paragraph">审计人员发现，有一种药物已在进行人体测试，研究人员却并未报告其动物试验结果，这一违规行为被一名医学伦理学家称为药品研究领域的“弥天大罪”。审计人员还得出结论，该研发中心的雇员并未适当地监测临床试验，并且以可以被视为行贿的方式向医院付钱。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Last year, Glaxo said, a more favorable audit found the concerns had been addressed. But several outside experts said the problems outlined in the initial audit were grave and painted a picture of an organization that failed to keep tabs on a crucial research center as it expanded both in size and scope. And it indicates that the problems there were more extensive than were reported in June, when the company fired the head of research and development in China after discovering that an article he helped write in the journal <a rel="noopener noreferrer" target="_blank" href="http://www.nature.com/nm/journal/v16/n2/full/nm.2077.html">Nature Medicine</a> contained misrepresented data.</div></div><div class="col-lg-6"><div class="article-paragraph">去年，GSK称，一次更为乐观的审计显示，这些担忧都已得到解决。但一些外部专家表示，第一次的审计发现的问题相当严重，说明该公司未能密切监督旗下一个至关重要的研究中心，当时该中心的规模和研究范围都在扩展。此外，那次审计表明问题比6月份报道的更为广泛，当时该公司解雇了中国的研发负责人，原因是发现他帮助撰写的一篇发表在《自然医学》期刊上的文章含有错误数据。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In a statement, Glaxo said it was committed to conducting “robust” audits of its business practices, and in this instance, “the process worked exactly as intended.” It added, “Patient safety is paramount and the audit reports do not show that this was compromised.”</div></div><div class="col-lg-6"><div class="article-paragraph">在一份声明中，GSK表示自己致力于对自身业务实践开展“严格”的审计，在这个例子中，“这一程序完全按照预期进行”。声明还补充说，“患者的安全至关重要，审计报告并未显示出这一点有所放松。”</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo’s research and development center opened in 2007 with lofty ambitions not only to help the company’s drugs get approved in China, but also to serve as one of its primary research hubs. The center grew quickly, expanding from one employee in 2007 to 460 in 2011, according to the audit. But as it grew, supervisors did not always ensure that the work done there was of high quality, auditors found.</div></div><div class="col-lg-6"><div class="article-paragraph">GSK的研发中心于2007年开业，其远大志向是不仅要帮助该公司的药品在中国得到批准，还要成为该公司主要的研究机构之一。根据审计报告，该中心发展迅速，雇员从2007年的一名扩大到了2011年的460名。但审计人员发现，随着它的增长，管理人员并不总是能确保工作的高水准。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">One of the most troubling lapses — a problem the report labeled “critical” — involved a drug known as ozanezumab, which was being developed to treat patients with multiple sclerosis and Lou Gehrig’s disease.</div></div><div class="col-lg-6"><div class="article-paragraph">最为令人不安的失误之一是报告中标记为“关键”的一个问题，涉及一种被称为ozanezumab的药物，开发该药的目的是治疗多发性硬化和卢·格里克病(Lou Gehrig’s disease)患者。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The report revealed that the drug’s project leader belatedly learned the results of three studies of ozanezumab in mice. During their investigation, auditors came across six studies whose results had not been reported, even though early trials in humans were already under way.</div></div><div class="col-lg-6"><div class="article-paragraph">报告显示，该药的项目负责人未能及时获得ozanezumab该药在老鼠身上的三次试验结果。调查过程之中，审计人员发现有6项研究结果未见汇报，早期的人体测试却已在进行之中。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Reporting such information is crucial, ethicists said, because animal studies can identify safety risks and are among the main factors drug companies use to decide whether to pursue human trials.</div></div><div class="col-lg-6"><div class="article-paragraph">伦理学家称，汇报这些信息至关重要，因为动物研究可以指明安全风险，而且是制药公司决定是否继续进行人体测试的主要依据之一。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“If that’s true, it’s a mortal sin in research requirements,” said Arthur L. Caplan, the head of the division of medical ethics at NYU Langone Medical Center. He served as the chairman of an advisory committee on bioethics at Glaxo from 2005 to 2008. “No one could approve human trials without having that information available, scientifically or ethically. That’s kind of a Rock-of-Gibraltar-sized ethics violation.”</div></div><div class="col-lg-6"><div class="article-paragraph">“如果真是这样，那可真是研究准则上的弥天大罪，”纽约大学(NYU)朗戈内医学中心(Langone Medical Center)医学伦理部门负责人阿瑟·L·卡普兰(Arthur L. Caplan)说。他曾在2005到2008年期间担任GSK的生物伦理顾问委员会主席。“如果没有这些信息，没人可以批准人体测试，从科学和伦理学角度来看都是如此。这样的伦理违规行为简直跟直布罗陀岩一般大小。”</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The auditors said the results did not affect patient safety, but warned of the high stakes involved, saying participants could be exposed “to unnecessary risk or no benefit to the disease state.”</div></div><div class="col-lg-6"><div class="article-paragraph">审计人员称试验结果并未影响病人的安全，同时警告此事关系重大，称试验参与者可能被暴露在“不必要的风险中，或是无法减轻病情”。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo said that “when the full range of data from all the studies was reviewed, GSK determined that the efficacy would not be strong enough to continue,” and it terminated a trial of ozanezumab in multiple sclerosis patients. It is still studying the drug in people with Lou Gehrig’s disease, or amyotrophic lateral sclerosis, <a rel="noopener noreferrer" target="_blank" href="http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=112264&amp;studyId=0058899A-AB7E-4890-97DE-E602F67A28EB&amp;compound=Ozanezumab">according to the company.</a></div></div><div class="col-lg-6"><div class="article-paragraph">GSK称，“在审查了所有研究的全系列研究数据之后，GSK确定其功效不足以说服公司继续研发”，并且终止了该药物在多发性硬化患者身上的ozanezumab试验。<a rel="noopener noreferrer" target="_blank" href="http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=112264&amp;studyId=0058899A-AB7E-4890-97DE-E602F67A28EB&amp;compound=Ozanezumab">据该公司称</a>，它仍然在卢·格里克病，即肌萎缩性脊髓侧索硬化症患者身上测试这种药物。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In the follow-up audit, auditors said senior managers at the Chinese research unit had “embedded a compliance culture that was not evident during the prior audit,” and did not find any issues of concern, according to an executive summary of the report that was provided by Glaxo.</div></div><div class="col-lg-6"><div class="article-paragraph">根据GSK所提供报告的纲要，在后续审计中，审计人员称中国研究部门的高级经理已经“融入了一种在之前审计中表现并不明显的合规文化”，并且没有发现任何令人担忧的问题。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Outside ethics experts said the report raised questions about whether patient safety was adequately protected.</div></div><div class="col-lg-6"><div class="article-paragraph">外部伦理专家称，该报告让人们质疑，病患安全是否得到了充分的保护。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Auditors found that Glaxo employees failed to record whether research participants had signed new consent forms during the course of clinical trials. They also did not document whether participants were taking the planned dosage of drugs, or whether they followed up when they learned that participants were not following a clinical trial’s protocol.</div></div><div class="col-lg-6"><div class="article-paragraph">审计人员发现，GSK雇员未能记录研究参与者是否在临床试验过程中签了新的同意表格，没有记录参与者是否服用了计划剂量的药物，也没有记录他们是否在发现参与者不遵守临床试验规定的情况下进行了跟进。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In the statement, Glaxo said that employees were properly monitoring trials but acknowledged that they were not adequately documenting their work. The company said it had corrected the problem, and the later audit found that practices had improved.</div></div><div class="col-lg-6"><div class="article-paragraph">GSK在声明中称雇员充分地监督了试验，但也承认他们没有对自己的工作进行完善的记录。公司称已经改正了该问题，后来的那次审计也发现公司的做法确有改善。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The 2011 audit report also raised alarms about the way the Shanghai office was paying the people who were overseeing the company’s trials at outside hospitals or clinics. According to auditors, Glaxo was paying many sites a flat fee for the cost of a full-time coordinator, regardless of the number of participants enrolled in the trial.</div></div><div class="col-lg-6"><div class="article-paragraph">2011年的审计报告还敲响了一个警钟，即GSK上海办公室给在外部医院及诊所监督该公司试验的人付钱的行为。审计人员称，GSK向许多试验点支付聘请一名全职协调员的统一费用，并不考虑参与试验的人数。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">The report warned of “reputational, financial and/or regulatory action risk where payments made to investigators regardless of actual work completed are perceived as bribery or corruption.”</div></div><div class="col-lg-6"><div class="article-paragraph">报告警告这种做法会造成“名誉、金融或监管行动风险，向调查人员付酬的时候不考虑实际工作完成量，会被视为贿赂或腐败。”</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Chinese investigators have said that Glaxo participated in a widespread bribery and corruption scheme in which the company used travel agencies to funnel illegal payments to doctors and government officials to bolster drug sales, and authorities have said they are also looking into the practices of other pharmaceutical companies.</div></div><div class="col-lg-6"><div class="article-paragraph">中国调查人员称，GSK参与了大范围的贿赂及腐败活动。GSK利用旅行社向医生及政府官员支付非法酬劳，以推动药品销售。官方称，他们也在调查其他药企的行为。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">On Monday, <a href="http://www.nytimes.com/2013/07/23/business/global/glaxo-says-executives-may-have-broken-chinese-law.html?_r=0">Glaxo said</a> that some of its executives might have broken the law.</div></div><div class="col-lg-6"><div class="article-paragraph">周一，GSK称，公司的一些高管可能违反了法律。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Outside experts said the payment of doctors and other hospital employees where trials were being conducted was tricky, because paying a fee based on the number of people enrolled in a study could also be seen as inappropriate.</div></div><div class="col-lg-6"><div class="article-paragraph">外部专家称，给试验点的医生及医院员工支付酬劳的行为很棘手，因为即使按照登记参与研究的人数付费也可以被视为不当行为。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“I’m much more concerned about people who are paid by the head to recruit,” said Dr. Campbell. Still, he said, if large payments were being made for little work, that could raise eyebrows. “It could be seen as simply another way to put money in people’s hands,” he said.</div></div><div class="col-lg-6"><div class="article-paragraph">坎贝尔说，“我特别担心那些按招来的人数收取酬劳的人。”但他又说，如果为很少的工作量支付很多的钱，同样令人震惊。他说，“那不过是换个方式把钱塞到人家手里而已。”</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Glaxo said it had since tightened the payment procedures for clinical research coordinators. Referring to the current bribery investigation, the company said, “we have zero tolerance for any kind of corrupt behavior among our employees, suppliers and business partners and will take action wherever and whenever we find it.”</div></div><div class="col-lg-6"><div class="article-paragraph">GSK称，从那以后，公司已经收紧了给临床研究协调员的酬劳。提到现在的贿赂调查时，GSK说，“我们对我们员工、供应商及业务合作伙伴的的任何腐败行为都持零容忍态度，一旦发现，我们会随时随地采取行动。”</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">In all, company officials said that appropriate steps were taken to address the issues outlined in the audit. And in 2011, auditors noted that leaders at the research center had recently tried to address the “significant issues” there.</div></div><div class="col-lg-6"><div class="article-paragraph">总而言之，公司方面称自己已经就审计中提出的问题采取了适当的行动。2011年，审计者注意到，该研究中心的领导曾在不久前试图应对那里的“重要问题”。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">Dr. Jerry Avorn, a professor at Harvard Medical School, and others gave credit to Glaxo for investigating one of its own research centers.</div></div><div class="col-lg-6"><div class="article-paragraph">哈佛大学医学院( Harvard Medical School)教授杰里·阿戎(Jerry Avorn)及其他一些人都对GSK自查旗下研究中心的举动表示称赞。</div></div></div><div class="row article-dual-body-item"><div class="col-lg-6"><div class="article-paragraph">“It is good that they detected these problems and vowed to fix them,” Dr. Avorn said, “but this report shows what can happen when a drug company rapidly expands its clinical research programs overseas without adequate quality controls.”</div></div><div class="col-lg-6"><div class="article-paragraph">他说，“他们发现了这些问题，并且誓言改正，这么做很好。但这份报告还是告诉我们，如果一家药企在海外迅速扩大其临床研究计划，同时又没有足够的质量控制手段，会发生什么事情。”</div></div></div></div><div class="article-body-aside col-lg-3"></div></div></section></div><div class="col-lg-12 row author-info-container"><footer class="author-info"><p>David Barboza对本文有报道贡献。</p><p>翻译：林蒙克、梁英</p></footer></div></article><div class="container article-footer"><div class="row"><div class="col-lg-12 dual-refer-cont"><div class="related-cont"><h4>相关报道</h4><ul class="refer-list"><li class="article-refer"><div class="refer-list-item"><a href="../../c23gsk/index.html" title="葛兰素史克承认公司高管可能违法"><div><h3 class="refer-list-headline">葛兰素史克承认公司高管可能违法</h3><p class="refer-pubdate">2013年7月23日</p></div></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../20130722/c22drugs/index.html" title="葛兰素史克行贿案或涉更多制药商"><div><h3 class="refer-list-headline">葛兰素史克行贿案或涉更多制药商</h3><p class="refer-pubdate">2013年7月22日</p></div><img alt="葛兰素史克行贿案或涉更多制药商" src="../../../../../static01.nyt.com/images/2013/07/22/business/drug/drug-thumbLarge.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../20130718/c18glaxo/index.html" title="中国限制葛兰素史克英籍高管离境"><div><h3 class="refer-list-headline">中国限制葛兰素史克英籍高管离境</h3><p class="refer-pubdate">2013年7月18日</p></div></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../20130716/c16gsk/index.html" title="中国指葛兰素史克通过旅行社行贿"><div><h3 class="refer-list-headline">中国指葛兰素史克通过旅行社行贿</h3><p class="refer-pubdate">2013年7月16日</p></div><img alt="中国指葛兰素史克通过旅行社行贿" src="../../../../../static01.nyt.com/images/2013/07/16/business/global/16drug/16drug-thumbLarge-v2.html" width="75" height="75"></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../20130702/c02drug/index.html" title="葛兰素史克中国高管遭调查"><div><h3 class="refer-list-headline">葛兰素史克中国高管遭调查</h3><p class="refer-pubdate">2013年7月2日</p></div></a></div></li><li class="article-refer"><div class="refer-list-item"><a href="../../../20120703/c03glaxo/index.html" title="葛兰素史克认缴30亿美元罚款"><div><h3 class="refer-list-headline">葛兰素史克认缴30亿美元罚款</h3><p class="refer-pubdate">2012年7月3日</p></div></a></div></li></ul></div></div><div class="col-lg-12"><div class="related hot_article"><h5 class="related-title">最受欢迎</h5><ol class="related-articles"><li><a href="#https://cn.nytimes.com/usa/20220127/computer-chip-shortage-taiwan/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>战棋推演报告称台湾半导体工厂停产可能引发中美冲突</h4><img alt="战棋推演报告称台湾半导体工厂停产可能引发中美冲突" src="../../../../../static01.nyt.com/images/2022/01/26/us/politics/26dc-wargames/merlin_177315390_5fcf8532-e370-4f81-8f99-45c6c83044f4-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/pakistan-united-states-china/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>“巴铁”军方为什么想与中国保持距离？</h4><img alt="“巴铁”军方为什么想与中国保持距离？" src="../../../../../static01.nyt.com/images/2022/01/24/opinion/21Rafiq1/21Rafiq1-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220126/china-covid-19/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>中国追求“清零”将把国家置于灾难之中</h4><img alt="中国追求“清零”将把国家置于灾难之中" src="../../../../../static01.nyt.com/images/2022/01/25/opinion/25emanuel/25emanuel-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/sports/20220127/peng-shuai-china-australian-open/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>澳网再现“彭帅在哪里”：球员和观赛者拒绝遗忘、为其发声</h4><img alt="澳网再现“彭帅在哪里”：球员和观赛者拒绝遗忘、为其发声" src="../../../../../static01.nyt.com/images/2022/01/26/sports/26aus-china1/merlin_199503951_9c695f25-2b8e-41b4-9c97-bf91de7aa190-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/usa/20220125/gang-chen-mit-china/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>“我们在残害我们自己”：华裔教授陈刚案背后的愤怒与幻灭</h4><img alt="“我们在残害我们自己”：华裔教授陈刚案背后的愤怒与幻灭" src="../../../../../static01.nyt.com/images/2022/01/24/science/24CHEN-promo/24CHEN-promo-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/opinion/20220127/virtual-reality-simulation/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>我们可能活在模拟现实中，人类应该多担忧这件事？</h4><img alt="我们可能活在模拟现实中，人类应该多担忧这件事？" src="../../../../../static01.nyt.com/images/2022/01/26/opinion/26manjoo-image/26manjoo-image-thumbLarge.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/winter-olympics-china-beijing-xi-jinping/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>不再取悦世界：一届展现习近平全面愿景的冬奥会</h4><img alt="不再取悦世界：一届展现习近平全面愿景的冬奥会" src="../../../../../static01.nyt.com/images/2022/01/13/world/00xi-olympics-30/00xi-olympics-30-thumbLarge.jpg"></article></a></li><li><a href="../../../20220126/imf-world-economic-report/indexf61c.html?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>国际货币基金组织称中美经济放缓将拖累全球经济</h4><img alt="国际货币基金组织称中美经济放缓将拖累全球经济" src="../../../../../static01.nyt.com/images/2022/01/25/multimedia/25global-econ-brf/25global-econ-brf-thumbLarge-v2.jpg"></article></a></li><li><a href="#https://cn.nytimes.com/asia-pacific/20220126/north-korea-launches-missiles-kim/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>朝鲜突然频繁试射导弹传递了什么信息？</h4><img alt="朝鲜突然频繁试射导弹传递了什么信息？" src="../../../../../static01.nyt.com/images/2022/01/21/world/00nkorea-gameplan-01/00nkorea-gameplan-01-thumbLarge.html"></article></a></li><li><a href="#https://cn.nytimes.com/china/20220124/china-zero-covid-policy/?utm_source=top10-in-article&amp;utm_medium=articlepage&amp;utm_campaign=web"><article><h4>多地封锁引发沮丧与抱怨，中国“清零”政策还能走多远？</h4><img alt="多地封锁引发沮丧与抱怨，中国“清零”政策还能走多远？" src="../../../../../static01.nyt.com/images/2022/01/20/world/00virus-china-lockdown-01/00virus-china-lockdown-01-thumbLarge.html"></article></a></li></ol></div></div></div></div></div><footer class="row copy-footer">&copy; 2022 The World Economy Observer.<ul class="footerLinkList"><li class="footerLink"><a rel="nofollow" href="/ad/">广告</a></li><li class="footerLink"><a rel="nofollow" href="/about-us/">关于我们</a></li><li class="footerLink"><a rel="nofollow" href="/contact/">联系我们</a></li><li class="footerLink"><a rel="nofollow" href="/tos/">服务条款</a></li><li class="purr-content"></li></ul></footer><script src="/d1f1eryiqyjs0r.cloudfront.net/js/libs/require619b.js?v=f1810d8"></script><script src="/d1f1eryiqyjs0r.cloudfront.net/js/web/article.min619b.js?v=f1810d8"></script></main></body>
<!-- Mirrored from cn.nytimes.com/business/20130723/c23drug/dual/ by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 28 Jan 2022 14:18:31 GMT -->
</html>